Abstract 5929
Background
Data for metastatic soft tissue sarcoma (STS) is sparse from developing countries. Pazopanib has demonstrated promising activity in the management of this disease. This study was carried out in the dedicated sarcoma medical oncology clinic in a tertiary referral center of Western India.
Methods
This is a retrospective analysis of prospective database from adult sarcoma medical oncology clinic at Tata Memorial Center, Mumbai from January 2035 to December 2018. The patients were provided holistic care through involvement of palliative care team, government fundings, local NGOs and sarcoma support groups. All statistical calculations were done using SPSS version 20.
Results
A total of 314 patients diagnosed with metastatic STS were registered in the dedicated medical oncology sarcoma clinic, 72% were males and median age 46 (16-79) years. Out of 314 patients, 60 (19%) patients received Pazopanib at some point of time during their treatment. Most common histology was synovial sarcoma (28%), leiomyosarcoma (26%), unspecified high grade spindle cell sarcoma (19%) and alveolar soft part sarcoma (12%). The median follow up duration was 18 (4-41) months. Median lines of prior therapy were 2 (0-2). Among 42 evaluable patients, there were 24% partial responses, 48% stable disease and 28% progressive disease. Median progression free survival was 5 (95% CI 3-7.3) months and median overall survival was 11 (95% CI 6.8-16.2) months. Important adverse events (>grade 1) included hand foot syndrome (10%), diarrhea (10%), hypothyroidism (10%), fatigue (8%) and hyperbilirubinemia/transaminitis (8%). Notably 50% patients required dose reduction and median dose was 600(200-800) mg daily.
Conclusions
Pazopanib was found to be a feasible treatment option for metastatic STS in India with internationally comparable outcomes. Median tolerated dose was lower than the standard 800 mg dose. Outcomes could be improved due to dedicated clinic with availability of targeted therapy with government help and local NGOs. This model of providing holistic care can be replicated in rare tumors in developing countries.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tata Memorial Hospital, Mumbai.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3245 - BCR-ABL transcript variant’s significance in chronic myeloid leukemia in chronic phase: Institutional experience from a developing country
Presenter: Siva Prasad
Session: Poster Display session 1
Resources:
Abstract
2831 - Interleukin-6 as a Predictive Marker for Early Response to Induction Chemotherapy in Acute Myeloblastic Leukaemia
Presenter: Salah Khallaf
Session: Poster Display session 1
Resources:
Abstract
6014 - Impact of FLT3-ITD mutation on post-transplant outcome of adult AML is modified by the concomitant NPM1 mutation and pre-transplant remission status: A report from Taiwan Bone Marrow Transplant Registry (TBMTR)
Presenter: Su-peng Yeh
Session: Poster Display session 1
Resources:
Abstract
2914 - Efficacy endpoints studied in clinical trials for early-onset leukaemia
Presenter: Dylan Said
Session: Poster Display session 1
Resources:
Abstract
4691 - High triglyceride is a major risk factor of DIC and differentiation syndrome in acute promyelocytic leukemia
Presenter: Tomohiro Yamakawa
Session: Poster Display session 1
Resources:
Abstract
4395 - DREAMM 4: A Phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)
Presenter: Suzanne Trudel
Session: Poster Display session 1
Resources:
Abstract
2808 - A Phase 1 Study of HMPL-523, a Selective Oral Anti-Spleen Tyrosine Kinase Inhibitor, in Patients with Relapsed or Refractory Lymphoma
Presenter: Nathan Fowler
Session: Poster Display session 1
Resources:
Abstract
4403 - A Phase 1 Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Patients with Relapsed or Refractory Lymphoma
Presenter: Jonathon Cohen
Session: Poster Display session 1
Resources:
Abstract
3357 - A global patient-driven Facebook study in a very rare sarcoma: Health-related quality of life in Epithelioid Hemangioendothelioma (EHE) patients
Presenter: Marije Weidema
Session: Poster Display session 1
Resources:
Abstract
2475 - Qualitative study of patients’ experiences of living with and beyond a soft tissue sarcoma diagnosis: the impact of sarcoma specialist services
Presenter: Ana Martins
Session: Poster Display session 1
Resources:
Abstract